Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD0901 + unspecified PD-1 antibody |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD0901 | AZD-0901|AZD 0901|CMG901|CM-G901|CM G901 | CLDN18.2 Antibody 23 | AZD0901 is an antibody-drug conjugate (ADC) comprising an anti-CLDN18.2 antibody linked to the anti-microtubule agent monomethyl auristatin E (MMAE), which may induce antibody-dependent cellular cytotoxicity (ADCC) and inhibit tumor growth (PMID: 39232496). | |
| unspecified PD-1 antibody | Experimental PD-1 antibody | Immune Checkpoint Inhibitor 150 PD-L1/PD-1 antibody 132 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|